Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Express Scripts has agreed to provide specialty pharmacy and specialty distribution services for Regeneron's Eylea, through its HealthBridge Pharma & Biotech services, CuraScript.
Subscribe to our email newsletter
Eylea (aflibercept) Injection is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) which is a major cause of blindness in older adults.
The injection secured approval from the Food and Drug Administration (FDA) on 18 November 2011.
Express Scripts business development senior director Rob Osborne said the number of people affected by macular degeneration is increasing due to rise in aging population.
"HealthBridge Pharma & Biotech is proud to provide services that will help patients get the medication they need to treat this debilitating disease," Osborne added.